Kezar Life Sciences (NASDAQ:KZR) Shares Up 2.4% – Still a Buy?

Kezar Life Sciences, Inc. (NASDAQ:KZR)’s share price traded up 2.4% during mid-day trading on Wednesday . The stock traded as high as $6.62 and last traded at $6.39. 32,828 shares were traded during mid-day trading, a decline of 3% from the average session volume of 33,745 shares. The stock had previously closed at $6.24.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. William Blair reaffirmed a “market perform” rating on shares of Kezar Life Sciences in a report on Wednesday, November 13th. Wells Fargo & Company dropped their price target on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating for the company in a research report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Kezar Life Sciences in a report on Monday, December 2nd.

Kezar Life Sciences Price Performance

The company’s 50 day moving average price is $6.61 and its 200 day moving average price is $6.75. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.65 and a current ratio of 7.65. The company has a market cap of $46.65 million, a price-to-earnings ratio of -0.48 and a beta of 0.19.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.78) earnings per share for the quarter, topping the consensus estimate of ($3.03) by $0.25. On average, equities research analysts predict that Kezar Life Sciences, Inc. will post -4.39 earnings per share for the current fiscal year.

Institutional Trading of Kezar Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd grew its holdings in Kezar Life Sciences by 256.1% during the 3rd quarter. XTX Topco Ltd now owns 52,148 shares of the company’s stock worth $40,000 after acquiring an additional 37,504 shares during the last quarter. Mackenzie Financial Corp bought a new stake in shares of Kezar Life Sciences during the second quarter valued at approximately $35,000. Geode Capital Management LLC increased its holdings in shares of Kezar Life Sciences by 15.0% in the third quarter. Geode Capital Management LLC now owns 626,912 shares of the company’s stock valued at $485,000 after purchasing an additional 81,678 shares in the last quarter. Peapod Lane Capital LLC bought a new position in Kezar Life Sciences in the 4th quarter worth approximately $833,000. Finally, Ikarian Capital LLC lifted its holdings in Kezar Life Sciences by 23.0% during the 3rd quarter. Ikarian Capital LLC now owns 1,068,992 shares of the company’s stock worth $827,000 after buying an additional 200,000 shares in the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.